US Stock MarketDetailed Quotes
SNPX Synaptogenix
- 3.0700
- +0.5050+19.69%
Close Dec 20 16:00 ET
4.16MMarket Cap3.49P/E (TTM)
3.1500High2.7500Low96.24KVolume2.7500Open2.5650Pre Close292.00KTurnover7.24%Turnover RatioLossP/E (Static)1.36MShares8.775052wk High0.33P/B4.08MFloat Cap2.320052wk Low--Dividend TTM1.33MShs Float362.5000Historical High--Div YieldTTM15.60%Amplitude2.3200Historical Low3.0330Avg Price1Lot Size
Synaptogenix Stock Forum
Sign in to post a comment
$Crown Electrokinetics (CRKN.US)$ $Dermata Therapeutics (DRMA.US)$ $KORE Group (KORE.US)$ $Vivakor (VIVK.US)$ $Rent the Runway (RENT.US)$ $iCoreConnect (ICCT.US)$ $My Size (MYSZ.US)$ $Synaptogenix (SNPX.US)$ $Eupraxia Pharmaceuticals (EPRX.US)$ $Live Ventures (LIVE.US)$ $Worksport (WKSP.US)$ $Gaxos.ai (GXAI.US)$ $Tharimmune (THAR.US)$ $MEDIROM Healthcare Technologies (MRM.US)$
📊⚡️📊
📊⚡️📊
2
2
$Synaptogenix (SNPX.US)$ Synaptogenix Enters Into Securities Purchase Agreements For A $5M Financing With Existing Investors Involving The Sale Of 5,000 Shares Of Its Newly Issued Series C Convertible Preferred Stock, With A Stated Value Of $1,000 Per Share; The Shares Of Series C Preferred Stock Have An Initial Conversion Price Of $4.00 Per Share And Accrue A 5.0% Quarterly Dividend Payable In Cash
$Synaptogenix (SNPX.US)$
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will com...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will com...
$Synaptogenix (SNPX.US)$ Reuters· just
Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
1
K promising?
my man
Synaptogenix, Inc. (NASDAQ: SNPX) has recently made headlines with its significant achievement in the field of neurodegenerative disease treatment. The pioneering biopharmaceutical company has received a Notice of Allowance for its U.S. Patent Application 17/665,033 titled "Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Ne...
3
$Synaptogenix (SNPX.US)$ Synaptogenix Has Received A Notice Of Allowance For Its U.S. Patent Application 17/665,033 Titled "Halogenated Esters Of Cyclopropanated Unsaturated Fatty Acids For Use In The Treatment Of Neurodegenerative Diseases"![]()
1
1
$Synaptogenix (SNPX.US)$ Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
1
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
MARKET-TEST-DUMMY :
MARKET-TEST-DUMMY : Couple on here for sure